Back to results
US 6,559,159 B2Granted
Kappa opioid receptor ligands
AssigneeResearch Triangle Institute
InventorsF. Ivy Carroll, James B. Thomas, S. Wayne Mascarella
Life of this patent
Estimating the term…
Abstract
Structurally novel kappa opioid receptor antagonists are provided and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
Claims24
A method of inducing kappa opioid receptor antagonism in a subject in need thereof, comprising:
- administering to said subject a composition comprising a kappa opioid receptor antagonist and a physiologically acceptable carrier, wherein the kappa opioid receptor antagonist is a compound of formula (I):
- wherein R1 is C2-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C1-8 alkylaryl or one of the following groups:
- R2 is a member selected from the group consisting of formulae (a)-(pp):
- X is NR, O or S;
- Y is OH, OR9, C1-8 alkyl, F, Cl, or CF3;
- R is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C1-8 alkylaryl, CO2R9
- W is a member selected from the group consisting of:
- H, OH, OCOR9;
- amino, —NR3SO2R9 and —NR3CO2R9;
- Z is NR3 or O;
- n is 1, 2 or 3;
- m is 1, 2, 3 or 4;
- j is 2, 3 or 4;
- k is 1 or 2;
- R3 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R4 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R5 and R6 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R7 and R8 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- and
- R9 is C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl.
17 more elements
A kappa opioid receptor antagonist compound represented by the formula (I):
- wherein R1 is C2-8 alkyl, C3-8 alkenyl, C1-8 alkynyl, C1-8 alkylaryl or one of the following groups:
- R2 is a member selected from the group consisting of formulae (a)-(pp):
- X is NR, O or S;
- Y is OH, OR9, C1-8 alkyl, F, Cl, or CF3;
- R is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C1-8 alkylaryl, CO2R9
- W is a member selected from the group consisting of:
- H, OH, COOR9;
- amino, —NR3SO2R9 and —NR3CO2R9;
- Z is NR3 or O;
- n is 1, 2 or 3;
- m is 1, 2, 3 or 4;
- j is 2, 3 or 4;
- k is 1 or 2;
- R3 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R4 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R5 and R6 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R7 and R8 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- and
- R9 is C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl.
16 more elements
A pharmaceutical composition comprising:
- an effective amount of a kappa opioid receptor antagonist and a physiologically acceptable carrier, wherein the kappa opioid receptor antagonist is a compound of formula (I):
- wherein R1 is C2-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C1-8 alkylaryl or one of the following groups:
- R2 is a member selected from the group consisting of formulae (a)-(pp):
- X is NR, O or S;
- Y is OH, OR9, C1-8 alkyl, F, Cl, or CF3;
- R is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C1-8 alkylaryl, CO2R9
- W is a member selected from the group consisting of:
- H, OH, COOR9;
- amino, —NR3SO2R9 and —NR3CO2R9;
- Z is NR3 or O;
- n is 1, 2 or 3;
- m is 1, 2, 3 or 4;
- j is 2, 3 or 4;
- k is 1 or 2;
- R3 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R4 is hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R5 and R6 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- R7 and R8 are each independently, hydrogen, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl;
- and
- R9 is C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, or C1-8 alkylaryl.
17 more elements
A method of inducing kappa opioid receptor antagonism in a subject in need thereof, comprising:
- administering to said subject a composition comprising a kappa opioid receptor antagonist and a physiologically acceptable carrier, wherein the kappa opioid receptor antagonist is a compound of formula 12 or 13
A kappa opioid receptor antagonist compound represented by formula 12 or 13
A pharmaceutical composition comprising:
- an effective amount of a kappa opioid receptor antagonist and a physiologically acceptable carrier, wherein said kappa opioid receptor antagonist is a compound of formula 12 or 13
Dependencies are inferred from the claim text.